Insulet Corporation (PODD) Stock Analysis
Price: $142.54 · +0.18% · Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
Company Overview
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Headquarters: ACTON, MA · Employees: 5,400 · Website ↗
Financial Health Scores
- Health Score
- 80/100
- strong
- Profitability
- 83/100
- strong
- Valuation Score
- 95/100
- strong
- Piotroski F-Score
- 7/9
- Altman Z-Score
- 4.67
- Safe zone
- Revenue CAGR
- 25.30%
- Net Income CAGR
- 95.84%
- FCF Margin
- 14.33%
- Debt Repayment
- 2.2 yrs
- Margin Stability
- 6.91%
Neutral
Analyst Consensus
BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 9, 2026
PMP Score
Coming soonA point-in-time composite score ranking future winners — built on the same data you see above.
- Earnings35%
- Awaiting PIT data
- Fundamentals30%
- Live — see scores above
- Momentum25%
- Awaiting PIT data
- Quality10%
- Awaiting PIT data
The earnings pillar requires timestamped analyst-consensus history (point-in-time verified) — currently in vendor procurement. No score is published until the data passes the PIT integrity gate.